Immunosuppressant therapy during gestation
Identifieur interne : 002938 ( Main/Exploration ); précédent : 002937; suivant : 002939Immunosuppressant therapy during gestation
Auteurs : Bertis B. Little [États-Unis]Source :
- Seminars in Perinatology [ 0146-0005 ] ; 1997.
English descriptors
- Teeft :
- Alkylating agents, Animal studies, Anomaly, Arthritis, Arthritis rheum, Autoimmune diseases, Azathioprine, Birth defects, Birth weight, Breast milk, Case report, Chloroquine, Cleft palate, Congenital, Congenital anomalies, Cyclosporine, Fetal, Fetal development, Fetal growth restriction, First trimester, Gold salts, Gold therapy, Gravid patients, Gynecol, Heart transplant recipients, Immune system, Immunosuppressant, Immunosuppressive agents, Inflammatory bowel disease, Maternal side effects, Medical center, Obstet, Obstet gynecol, Prednisone, Pregnancy, Pregnancy outcome, Pregnant women, Renal, Renal allograft recipients, Renal transplant mothers, Renal transplant patients, Renal transplant recipients, Renal transplantation, Rheumatoid arthritis, Steroid, Transplant, Transplantation, Ulcerative colitis.
Abstract
Use of immunosuppressants during pregnancy is indicated for anti-rejection therapy in transplantation patients and treatment of autoimmune diseases. Maternal side effects include nephrotoxocity and hepatotoxicity. All immunosuppressant drugs cross the placenta. Immunosuppressant use during the first trimester is not strongly associated with an increased risk of congenital anomalies, although some agents (eg, azathioprine) may be associated with slightly increased frequencies of birth defects. Effects of exposure to this class of drugs during the second and third trimesters affect the fetus' immune system. The result is an infant with a transiently compromised immune system at an increased risk of slightly lower birth weight. Other direct toxic effects of the drugs on the infant's pancreas, liver, and lymphocytes are reported. Certain agents (eg, penicillamine, chloroquine) should be avoided during pregnancy, if possible. However, their use cannot be discontinued during pregnancy given the life-threatening nature of the indication for use of immunosuppressants.
Url:
DOI: 10.1016/S0146-0005(97)80057-2
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000E28
- to stream Istex, to step Curation: 000E28
- to stream Istex, to step Checkpoint: 001733
- to stream Main, to step Merge: 002988
- to stream Main, to step Curation: 002938
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Immunosuppressant therapy during gestation</title><author><name sortKey="Little, Bertis B" sort="Little, Bertis B" uniqKey="Little B" first="Bertis B." last="Little">Bertis B. Little</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4EF760C4BDBB7BA398134D3644A41C5D56D4B201</idno><date when="1997" year="1997">1997</date><idno type="doi">10.1016/S0146-0005(97)80057-2</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-3F5S4VR0-2/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000E28</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000E28</idno><idno type="wicri:Area/Istex/Curation">000E28</idno><idno type="wicri:Area/Istex/Checkpoint">001733</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001733</idno><idno type="wicri:doubleKey">0146-0005:1997:Little B:immunosuppressant:therapy:during</idno><idno type="wicri:Area/Main/Merge">002988</idno><idno type="wicri:Area/Main/Curation">002938</idno><idno type="wicri:Area/Main/Exploration">002938</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Immunosuppressant therapy during gestation</title><author><name sortKey="Little, Bertis B" sort="Little, Bertis B" uniqKey="Little B" first="Bertis B." last="Little">Bertis B. Little</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Obstetrics and Gynecology, The University of Texas Southwestern Medical Center, Dallas, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Seminars in Perinatology</title><title level="j" type="abbrev">YSPER</title><idno type="ISSN">0146-0005</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1997">1997</date><biblScope unit="volume">21</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="143">143</biblScope><biblScope unit="page" to="148">148</biblScope></imprint><idno type="ISSN">0146-0005</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0146-0005</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Alkylating agents</term><term>Animal studies</term><term>Anomaly</term><term>Arthritis</term><term>Arthritis rheum</term><term>Autoimmune diseases</term><term>Azathioprine</term><term>Birth defects</term><term>Birth weight</term><term>Breast milk</term><term>Case report</term><term>Chloroquine</term><term>Cleft palate</term><term>Congenital</term><term>Congenital anomalies</term><term>Cyclosporine</term><term>Fetal</term><term>Fetal development</term><term>Fetal growth restriction</term><term>First trimester</term><term>Gold salts</term><term>Gold therapy</term><term>Gravid patients</term><term>Gynecol</term><term>Heart transplant recipients</term><term>Immune system</term><term>Immunosuppressant</term><term>Immunosuppressive agents</term><term>Inflammatory bowel disease</term><term>Maternal side effects</term><term>Medical center</term><term>Obstet</term><term>Obstet gynecol</term><term>Prednisone</term><term>Pregnancy</term><term>Pregnancy outcome</term><term>Pregnant women</term><term>Renal</term><term>Renal allograft recipients</term><term>Renal transplant mothers</term><term>Renal transplant patients</term><term>Renal transplant recipients</term><term>Renal transplantation</term><term>Rheumatoid arthritis</term><term>Steroid</term><term>Transplant</term><term>Transplantation</term><term>Ulcerative colitis</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Use of immunosuppressants during pregnancy is indicated for anti-rejection therapy in transplantation patients and treatment of autoimmune diseases. Maternal side effects include nephrotoxocity and hepatotoxicity. All immunosuppressant drugs cross the placenta. Immunosuppressant use during the first trimester is not strongly associated with an increased risk of congenital anomalies, although some agents (eg, azathioprine) may be associated with slightly increased frequencies of birth defects. Effects of exposure to this class of drugs during the second and third trimesters affect the fetus' immune system. The result is an infant with a transiently compromised immune system at an increased risk of slightly lower birth weight. Other direct toxic effects of the drugs on the infant's pancreas, liver, and lymphocytes are reported. Certain agents (eg, penicillamine, chloroquine) should be avoided during pregnancy, if possible. However, their use cannot be discontinued during pregnancy given the life-threatening nature of the indication for use of immunosuppressants.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Texas</li></region></list><tree><country name="États-Unis"><region name="Texas"><name sortKey="Little, Bertis B" sort="Little, Bertis B" uniqKey="Little B" first="Bertis B." last="Little">Bertis B. Little</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002938 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002938 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:4EF760C4BDBB7BA398134D3644A41C5D56D4B201
|texte= Immunosuppressant therapy during gestation
}}
| This area was generated with Dilib version V0.6.33. |  |